On August 16, 2011, Dr. Covert and other members of the Houston psychiatric community were invited to an enjoyable scientific presentation by Dr. Larry Ereshefsky, Pharm D and Clinical Professor at the UTHSC San Antonio, TX , and now associated with UCLA Medical School In Los Angeles, California.
Dr. Larry discussed the sublingual neuroleptic medication, Saphris (aserapine), and it’s comparative properties, including:
- Optimal bioavailability
- Steady state concentration achieved in 3 days with twice daily administration
- Minimal drug-drug interactions
- FDA efficacy in significant mental disorders while minimizing sedation, lipid and weight gain problems and cognitive dulling as compared to other atypical neuroleptics like Seroquel and Zyprexa.
Posted on 8-17-2011
